secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2023-03-03T23:59:59+00:00
Accession:  0001193125-23-059077
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience CEO Brendan Delaney resigns; CFO Scott Giacobello named interim CEO
--------------------------------------------------------------------------------

- Brendan Delaney resigned as President, CEO, and director effective March 14, 2023, for personal reasons, not due to any disagreement.
- CFO Scott Giacobello appointed Interim CEO and President effective March 15, 2023, while retaining CFO role.
- Founder Neil Desai, Ph.D., continues as Executive Chairman and will assist with leadership transition.
- Board has initiated a search for a permanent CEO; Giacobello's interim role ends when successor is appointed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312523059077/0001193125-23-059077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312523059077/d377824d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-059077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer